Peer-Reviewed The Rediscovery of Bisantrene Published
Filed with ASX · · 1 page · English
Earlier from Racura Oncology
- Race Completes Over-Subscribed $2.5 Million Placement
- Race Joint Venture with TargImmune
- Race Announces NCI Collaboration
- Bisantrene License Agreement for Korea
- Pre-IND Meeting Confirms 505(b)(2) Pathway for Bisantrene
Later from Racura Oncology
- Issue of Options
- Appendix 4E & Annual Financial Statements
- Race Oncology Produces First Batch of Bisantrene
- Race Receives $170k R&D Tax Incentive Refund
- Notice of Allowance for Bisantrene Patent in US
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology